LNTH Stock Forecast 2025-2026
Distance to LNTH Price Targets
LNTH Price Momentum
🤔 Considering Lantheus (LNTH)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Latest LNTH Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, LNTH has a bullish consensus with a median price target of $134.00 (ranging from $110.00 to $166.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $101.10, the median forecast implies a 32.5% upside. This outlook is supported by 12 Buy, 1 Hold, and 0 Sell ratings.
Conversely, the most conservative target is provided by Richard Newitter at Truist Securities, suggesting a 8.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
LNTH Analyst Ratings
LNTH Price Target Range
Latest LNTH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for LNTH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 27, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $127.00 |
| Jan 14, 2025 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $112.00 |
| Dec 18, 2024 | Goldman Sachs | Paul Choi | Buy | Initiates | $143.00 |
| Nov 8, 2024 | Truist Securities | Richard Newitter | Buy | Reiterates | $120.00 |
| Nov 7, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $112.00 |
| Sep 3, 2024 | Redburn Atlantic | Ed Ridley-Day | Buy | Initiates | $175.00 |
| Aug 1, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $135.00 |
| Aug 1, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $125.00 |
| Jul 25, 2024 | B. Riley Securities | Justin Walsh | Buy | Maintains | $146.00 |
| Jul 19, 2024 | Jones Trading | Justin Walsh | Buy | Maintains | $137.00 |
| Jul 11, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $141.00 |
| Jul 11, 2024 | Leerink Partners | Outperform | Maintains | $127.00 | |
| May 3, 2024 | Mizuho | Anthony Petrone | Buy | Maintains | $100.00 |
| May 3, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $96.00 |
| Apr 18, 2024 | B. Riley Securities | Justin Walsh | Buy | Maintains | $99.00 |
| Feb 26, 2024 | Truist Securities | Richard Newitter | Buy | Reiterates | $82.00 |
| Feb 23, 2024 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $100.00 |
| Jan 10, 2024 | B. Riley Securities | Justin Walsh | Buy | Maintains | $95.00 |
| Dec 4, 2023 | TD Cowen | Boris Peaker | Outperform | Initiates | $100.00 |
| Nov 30, 2023 | Brookline Capital | Kemp Dolliver | Buy | Initiates | $100.00 |
Lantheus Holdings Inc. (LNTH) Competitors
The following stocks are similar to Lantheus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Lantheus Holdings Inc. (LNTH) Financial Data
Lantheus Holdings Inc. has a market capitalization of $6.90B with a P/E ratio of 23.1x. The company generates $1.53B in trailing twelve-month revenue with a 20.4% profit margin.
Revenue growth is +10.5% quarter-over-quarter, while maintaining an operating margin of +28.2% and return on equity of +32.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Lantheus Holdings Inc. (LNTH) Business Model
About Lantheus Holdings Inc.
Develops innovative diagnostic products for healthcare.
Lantheus Holdings generates revenue through the development, manufacture, and commercialization of diagnostic products, particularly in nuclear medicine. The company provides essential imaging tools that help healthcare professionals accurately diagnose conditions like cardiovascular diseases and cancer, thereby driving demand for its products in hospitals and clinics worldwide.
With a strong focus on research and development, Lantheus is at the forefront of enhancing diagnostic methodologies, contributing significantly to the shift towards precision medicine in healthcare. Its products, including contrast agents and radiopharmaceuticals, are crucial in improving the accuracy of imaging procedures, making Lantheus a key player in the medical technology sector.
Company Information
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
808
CEO
Mr. Brian A. Markison
Country
United States
IPO Year
2015
Website
www.lantheus.comLantheus Holdings Inc. (LNTH) Latest News & Analysis
Lantheus Holdings' stock is up 55% due to strong growth from Pylarify and Definity. Strategic acquisitions have diversified its pipeline, though Pylarify's patent expiration in 2026 poses a risk.
Lantheus Holdings' stock surge reflects strong revenue growth and strategic acquisitions, enhancing its market position. Patent risks on Pylarify highlight the need for ongoing innovation and revenue diversification.
Lantheus' Pylarify Hit $1B in 2024 Sales
16 days agoLantheus Holdings held its Q4 and full-year 2024 earnings call on Feb. 26, 2025, discussing successes in its radiopharmaceutical portfolio and revealing strategic transactions.
Lantheus Holdings' earnings call showcases growth in its radiopharmaceuticals and strategic moves, signaling potential for revenue increases and market expansion, impacting investor sentiment positively.
Lantheus Holdings (LNTH) is featured in a Motley Fool Scoreboard episode, offering insights into market trends and investment opportunities for potential investors.
The mention of Lantheus Holdings and expert analysis highlights potential investment opportunities and market trends, signaling possible growth or risk factors for investors to consider.
Lantheus Holdings, Inc. will hold its Q4 2024 earnings conference call on February 26, 2025, at 8:00 AM ET, featuring company executives and analysts from various financial firms.
The upcoming earnings call for Lantheus Holdings provides insights into financial performance and strategic direction, critical for assessing investment potential and market sentiment.
Lantheus Holdings (LNTH) announced a new acquisition, but the market reacted negatively, resulting in a loss of over 7% in its stock price.
Lantheus Holdings' stock drop indicates investor skepticism about the acquisition's value, potentially affecting future growth and profitability outlook.
Lantheus Holdings announced the acquisition of Evergreen Theragnostics for $250M upfront and up to $752.5M in milestones. The deal enhances Lantheus' radiopharmaceutical capabilities and pipeline.
Lantheus's acquisition of Evergreen enhances its radiopharmaceutical pipeline and infrastructure, potentially boosting revenue and market position in oncology, which may positively affect stock performance.
Frequently Asked Questions About LNTH Stock
What is Lantheus Holdings Inc.'s (LNTH) stock forecast for 2025?
Based on our analysis of 15 Wall Street analysts, Lantheus Holdings Inc. (LNTH) has a median price target of $134.00. The highest price target is $166.00 and the lowest is $110.00.
Is LNTH stock a good investment in 2025?
According to current analyst ratings, LNTH has 12 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $101.10. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for LNTH stock?
Wall Street analysts predict LNTH stock could reach $134.00 in the next 12 months. This represents a 32.5% increase from the current price of $101.10. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Lantheus Holdings Inc.'s business model?
Lantheus Holdings generates revenue through the development, manufacture, and commercialization of diagnostic products, particularly in nuclear medicine. The company provides essential imaging tools that help healthcare professionals accurately diagnose conditions like cardiovascular diseases and cancer, thereby driving demand for its products in hospitals and clinics worldwide.
What is the highest forecasted price for LNTH Lantheus Holdings Inc.?
The highest price target for LNTH is $166.00 from at , which represents a 64.2% increase from the current price of $101.10.
What is the lowest forecasted price for LNTH Lantheus Holdings Inc.?
The lowest price target for LNTH is $110.00 from Richard Newitter at Truist Securities, which represents a 8.8% increase from the current price of $101.10.
What is the overall LNTH consensus from analysts for Lantheus Holdings Inc.?
The overall analyst consensus for LNTH is bullish. Out of 15 Wall Street analysts, 12 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $134.00.
How accurate are LNTH stock price projections?
Stock price projections, including those for Lantheus Holdings Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
